Kymera Therapeutics, Inc. (KYMR) stock plunged 7.27% in early Thursday trading following the release of its disappointing fourth-quarter results. The biopharmaceutical company reported a wider net loss and lower collaboration revenue compared to the year-ago period, missing analyst estimates.
For the quarter ended December 31, 2024, Kymera Therapeutics posted a net loss of $0.88 per diluted share, significantly worse than the $0.25 loss in the same period a year earlier. The company's collaboration revenue for the quarter came in at $7.4 million, a substantial decrease from $47.9 million in the prior-year quarter. Both figures missed consensus analyst estimates.
The company highlighted its strong cash position of $851 million as of December 31, which is expected to fund operations into mid-2027. However, investors appeared to focus on the disappointing quarterly performance, driving the stock down in pre-market trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。